Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Lymphoma, Non-Hodgkin
  • Neoplasm Recurrence, Local
  • Polyethylene Glycols
  • Thrombopoietin

abstract

  • PEG-rHuMGDF ameliorated thrombocytopenia, improved platelet recovery, and maintained ICE dose intensity. Potential survival advantages conferred by maintaining dose intensity require validation with newer thrombopoietic agents.

publication date

  • November 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdm341

PubMed ID

  • 17872903

Additional Document Info

start page

  • 1842

end page

  • 50

volume

  • 18

number

  • 11